Fenofibrate and Sirolimus drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Fenofibrate (fenofibrate) and Sirolimus (sirolimus). Common drug interactions include bell's palsy among females and blood urea increased among males.

The phase IV clinical study analyzes what interactions people have when they take Fenofibrate and Sirolimus. It is created by eHealthMe based on reports of 72 people who take the same drugs from the FDA, and is updated regularly.

What is Fenofibrate?

Fenofibrate has active ingredients of fenofibrate. It is often used in high blood cholesterol. eHealthMe is studying from 40,456 Fenofibrate users. Check the latest studies of Fenofibrate.

What is Sirolimus?

Sirolimus has active ingredients of sirolimus. eHealthMe is studying from 11,823 Sirolimus users. Check the latest studies of Sirolimus.

On Jul, 15, 2026

72 people who take Fenofibrate and Sirolimus together, and have interactions are studied.

Fenofibrate and Sirolimus drug interactions.

What are the common drug interactions of Fenofibrate and Sirolimus, by gender? *:

female:

Bell's palsy (facial paralysis)
Bladder disorder
Blood pressure decreased
Blood pressure increased
Bruxism (habitual grinding of the teeth, typically during sleep)
Candidiasis (candidiasis or thrush is a fungal infection)
Decreased appetite
Dehydration (dryness resulting from the removal of water)
Dizziness
Dyspnoea exertional (breathlessness or shortness of breath)

male:

Blood urea increased
Glomerular filtration rate decreased
Proteinuria (presence of protein in the urine)
Pulmonary cavitation (cavity in the lung)
Rash
Acidosis (build-up of carbon dioxide in the blood)
Blood creatine phosphokinase increased
Chills (felling of cold)
Diarrhoea
Dysgeusia (disorder of the sense of taste)

What are the common drug interactions of Fenofibrate and Sirolimus, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Blood potassium increased

30-39:

Blood urea increased
Glomerular filtration rate decreased
Haemoglobin decreased
Urinary tract infection
Protein urine present
Proteinuria (presence of protein in the urine)
Renal failure (kidney dysfunction)
Erythema (redness of the skin)
Injection site erythema (redness at injection site)
Injection site pain

40-49:

Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
Immunosuppressant drug level increased
Pruritus (severe itching of the skin)
Pyrexia (fever)
Rash
Renal failure (kidney dysfunction)
Blood creatine phosphokinase increased
Low density lipoprotein increased (cholesterol increased in blood)
Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung)
Pulmonary cavitation (cavity in the lung)

50-59:

Headache (pain in head)
Tremor (trembling or shaking movements in one or more parts of your body)
Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
Abdominal pain upper
Acidosis (build-up of carbon dioxide in the blood)
Adverse drug reaction
Aggression
Agitation (state of anxiety or nervous excitement)
Back pain
Bell's palsy (facial paralysis)

60+:

Diarrhoea
Vomiting
Blood creatinine increased
Blood glucose increased
Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
Chills (felling of cold)
Cough
Feeling cold
Glomerular filtration rate decreased
Heart rate increased

What are the existing conditions these people have? *

High Blood Pressure: 12 people, 16.67%
Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 9 people, 12.50%
Anaemia (lack of blood): 6 people, 8.33%
Pain: 5 people, 6.94%
Lipids Increased (excess lipid in body): 5 people, 6.94%
Vasospasm (sudden constriction of a blood vessel, reducing its diameter and flow rate): 4 people, 5.56%
Urination - Excessive Volume: 4 people, 5.56%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 4 people, 5.56%
Red Blood Cell Count Decreased: 4 people, 5.56%
Heart Disease: 4 people, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Fenofibrate and Sirolimus?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously